Evidence map›Paper›PMID 41705302›Full record

ArticleAllergy2026

Interleukin-22 and Interleukin-18 as Potential Blood Biomarkers in Dupilumab-Treated Atopic Dermatitis.

Ayano Fukushima-Nomura, Hiroshi Kawasaki, Takehiro Hasegawa, Erika Yanagisawa, Keiji Tanese, Nozomi Yanagida, Shoko Obata, Kiyoshi Yashiro, Yoshihiro Ito, Haruhiko Koseki and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ayano Fukushima-NomuraDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9482-5008
Hiroshi KawasakiDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6290-5102
Takehiro HasegawaCentral Research Laboratories, Sysmex Corporation, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4635-4942
Erika YanagisawaDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Keiji TaneseDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1409-6475
Nozomi YanagidaDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0574-539X
Shoko ObataDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Kiyoshi YashiroDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0009-0003-4858-5706
Yoshihiro ItoDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3536-4819
Haruhiko KosekiLaboratory for Developmental Genetics, RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Japan.ORCID https://orcid.org/0000-0001-8424-5854
Masayuki AmagaiDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3314-7052

Funding

Japan Agency for Medical Research and DevelopmentJapan Science and Technology AgencyJapan Society for the Promotion of ScienceMaruho Takagi Dermatology Foundation
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atopic dermatitisbiologicsbiomarkerIL‐18IL‐22

Identifiers

PMID41705302
PMCPMC13342774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.